Amgen

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 
 SiteOne Therapeutics is a biopharmaceutical company synthesizing small molecule inhibitors to treat hypersensitivity disorders such as chronic pain, itch, and cough. Compared to traditional treatments like opioids and nonsteroidal anti-inflammatory drugs (NSAID), SiteOne is developing a new class of non-opioid, non-NSAID pain treatments that selectively target and interrupt pain signals before they engage the central nervous system.
 
 
 The company&rsquo;s drug candidates target two voltage-gated sodium ion channels, NaV1.7 and NaV1.8, for various indications. As of July 2023, it had one program in Phase I clinical trials to treat acute pain. The company was also advancing additional candidates that would be used in the treatment of additional hypersensitivity disorders such as chronic cough and chronic ocular surface pain.&nbsp;
 
 
 Key Customers and Partnerships
 
 
 In January 2017, the company partnered with Amgen on an R&amp;D agreement to advance a portfolio of drugs targeting NaV1.7 inhibitors to treat acute and chronic pain. Furthermore, in January 2022, the company also collaborated with Vertex Pharmaceuticals to advance NaV1.7 inhibitors for the treatment for pain.&nbsp;
 
 
 Funding and Financials
 
 
 In May 2023, the company received a 
 <a href="https://sp-edge.com/updates/18713">
 grant
 </a>
 of up to USD 15 million from the National Institute on Drug Abuse. The grant was awarded to the company for the development of its drug candidate, STC-004, an investigational non-opioid treatment for acute and chronic pain conditions. 
 
</div>

<div>
 
 Oxford Nanopore Technologies is a spin-out from the University of Oxford that has developed a new generation of DNA/RNA sequencing technology which is claimed to be the only sequencing technology that offers real-time analysis, in fully scalable formats from pocket to population scale, which can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. This technology supports both scientific research and in a range of industries such as healthcare, industrial and other environments.
 
 
 
 
 Their product Flongle targets the need for on-demand, rapid, smaller tests or experiments. The pocket-sized MinION is a portable sequencing device that can reportedly deliver high volumes of long read sequence data. The benchtop GridION can apparently run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects. Their PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells - allowing delivery of over 10 Tb of sequence data in a full run, now used in population-scale sequencing projects. Also, the palm sized PromethION 2 is claimed to make high-output nanopore sequencing broadly accessible.
 
 
 
 
 To make the technology suitable for any user, the company was working on increasing ease of use and automation (as of October 2023). Nanopore sequencing reportedly offers easy and rapid preparation, including a ten minute library preparation kit and the automated, programmable VolTRAX in addition to a range of analysis workflows.
 
 
 
 
 The company employed over 1,000 employees (as of October 2023) from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Oxford Nanopore Technologies and Mayo Clinic announced a multi-year joint development collaboration in October 2023 to develop new clinical tests for diseases and improve patient care. The partnership intended to leverage Oxford Nanopore's nanopore sequencing technology to enhance Mayo Clinic's testing capabilities in areas such as human genetics and cancer detection. The collaboration will take place on Mayo Clinic's campus in Minnesota.
 
 
 
 
 The company also entered into a partnership with Swiss next-generation sequencing data analysis company Saphetor in October 2023, to allow tertiary analysis of the nanopore sequencing data for the purpose of variant interpretation and prioritization. Under the partnership, the companies intended to create a direct connection between secondary and tertiary analysis of nanopore sequencing data through the integration of Oxford Nanopore's Epi2Me research software with Saphetor's VarSome Clinical (a clinically accredited platform allowing variant discovery, annotation, and interpretation of NGS data for whole genomes, exomes, and gene panels).&nbsp;
 
 
 
 
 Funding and financials
 
 
 
 
 In October 2023, Oxford Nanopore Technologies raised GBP 70 million in a private placement from biotechnology company bioM&eacute;rieux S.A. This investment was earmarked to support development of products in Oxford Nanopore&rsquo;s portfolio to serve IVD markets. 
 
 
 Note
 : 
 Oxford Nanopore Technologies is non-
 comparable as its sequencing technology is unique.
 
</div>

<div>
 
 SomaLogic is a proteomics company offering protein biomarker discovery and clinical diagnostics services to support drug development and precision medicine. Its proprietary SomaScan platform can measure 7,000 proteins in the human body, with plans to reach 10,000 by 2023.&nbsp;
 
 
 The company provides two core services - SomaScan Discovery for large-scale protein detection and SomaSignal Tests which analyze patient samples for disease risk assessment. SomaSignal leverages a bioinformatics algorithm built on over 450,000 protein samples. To enhance its proteomics capabilities, SomaLogic acquired DNA nanotechnology firm 
 <a href="https://sp-edge.com/updates/11889">
 Palamedrix
 </a>
 in 2022 for its technology to improve SomaScan's accessibility and usage. The company&rsquo;s technology is built on two decades of research and development, and, as of November 2022, had over 600 patents covering areas such as chemistry, data analytics, diagnostics, and therapeutic.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company had entered into several strategic collaborations in private and public entities for drug discovery and development including a 10-year agreement with 
 <a href="https://sp-edge.com/companies/12122">
 Novartis 
 </a>
 , a multi-year partnership agreement with 
 <a href="https://sp-edge.com/companies/36695">
 Illumina 
 </a>
 , an agreement with precision oncology company, 
 <a href="https://sp-edge.com/companies/812083">
 OncoHost 
 </a>
 , 
 and a partnership with 
 <a href="https://sp-edge.com/updates/19329">
 Citagen 
 </a>
 and 
 <a href="https://sp-edge.com/updates/20375">
 Dante Genomics
 </a>
 .&nbsp;
 
 
 Funding and Financials
 
 
 The company began trading on Nasdaq in September 2021 under the ticker symbol &ldquo;SLGC,&rdquo; raising USD 630 million at IPO. For 
 <a href="https://sp-edge.com/updates/17357">
 2022 
 </a>
 revenue increased 20% YoY to USD 97.7 million and the net loss worsened by 24.8% YoY to USD 109.2 million. 
 <a href="https://sp-edge.com/updates/18743">
 In Q1 2023 
 </a>
 , net losses increased considerably by more than 7x YoY to USD 34.2 million while revenue decreased 11% YoY to USD 20.4 million. The company expects revenue for the full-year 2023 in the range of USD 80 million&ndash;84 million, implying a 12%&ndash;17% decrease, excluding licensing revenue from New England Biolabs.
 
</div>

<div>
 
 Neumora Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicine for neuropsychiatric disorders and neurodegenerative diseases. The company&rsquo;s proprietary computational platform leverages machine learning, data science, and neuroinformatics to map novel drug targets to specific areas of the brain to address brain diseases and mental health conditions.&nbsp;
 
 
 Launched in 2021, Neumora emerged with seven drug programs that were discovered in-house, via acquisitions of multiple private companies (including BlackThorn Therapeutics) and license agreements with Amgen. The company&rsquo;s lead drug candidate, NMRA-140, is a selective antagonist for the kappa opioid receptor (KOR) in Phase 2 clinical trials for patients with major depressive disorder. It is intended to reduce stress responses, providing a novel therapeutic approach to treating neurobehavioral disorders. Its other clinical-stage (Phase 1) drug candidate, NMRA-511, is being developed for anxiety disorder.
 
 
 Funding and Financials
 
 
 The firm raised its latest funding in October 2022 amounting to USD 112 million in a Series B funding round co-led by Mubadala Capital, Abu Dhabi Growth Fund and Amgen. The new funds were allocated towards advancing its drug development pipeline into clinical and preclinical trials and developing its neuroscience platform. 
 
</div>

Accure Health is a company focused on developing innovative digital diagnostics technologies to improve the speed and accuracy of disease detection and treatment delivery for patients. The company's core technology is the integrated magneto-electronic sensing (iMES), which was initially developed by its cofounders at Harvard Medical School and Massachusetts General Hospital. Accure's iMES technology rapidly digitizes liquid biomarkers and immune signatures into quantitative, actionable information for disease detection and therapeutic monitoring. It incorporates proprietary reagents, circuits, and algorithms into one compact system, bypassing the limitations of existing optical diagnostic devices.Accure has also developed a next-generation system called TiMES, which features an automated, multiplex assay process and real-time data analyses with secure cloud integration. The TiMES system is compact and can be easily set up in an office or home setting. It allows for the rapid analysis of low-abundance immune biomarkers such as neutralizing antibodies directly in saliva samples. This technology has been applied to develop a TiMES-Now Covid-19 neutralizing antibody test, which analyzes saliva samples and returns results in 30 minutes with 100 times better sensitivity than conventional lab tests. As of September 2021, Accure Health had published data demonstrating that their novel saliva assay could assess individual immune response to Covid-19 vaccines, monitor neutralizing antibody levels over time, and modelimmune protection against SARS-CoV-2 variants.The company has also demonstrated the clinical application of its iMES technology in cancer detection. A paper published in Nature Biomedical Engineering showed that the technology enabled high-throughput detection of colorectal cancer with over 96% accuracy. Accure Health has developed unique solutions for cancer, immune, and neurodegenerative diseases, and its technology can deliver approximately 75% time and cost savings on new test development and inform therapeutic strategy.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Jasper Therapeutics develops therapeutics through the editing of mast cells and stem cells for the treatment of oncology, dermatology, anemia, hematology, auto-immune, and genetic diseases. The company’s therapeutics use the editing of cell mRNA and DNA to help overcome issues with regard to allogeneic and autologous gene-edited stem cell grafts. The company is listed on the Nasdaq and trades under the ticker symbol JSPR after a merger with Special Purpose Acquisition Company (SPAC) Amplitude Healthcare in May 2021. As of May 2024, the company had one therapeutic candidate, Briquilimab, which was being tested across multiple applications. For Mast Cell Diseases, Briquilimab was being tested for the treatment of Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, and asthma. Its asthma application was in the preclinical stage, while its other two applications were in clinical testing phases. Briquilimab was also being tested for the treatment of two Stem Cell-related diseases, Low to Intermediate Risk Myelodysplastic Syndromes and Severe combined Immunodeficiency, both of which were in clinical testing phases. Jasper also had partner programs for treating Stem Cell-related diseases, testing Briquilimab for the treatment of Fanconi Anemia (in partnership with Stanford University), Sickle Cell Disease, Chronic Granulomatous Disease, and GATA2 MDS, all in partnership with the National Institute of Health.

Generate Biomedicines is a gene therapy developer that offers a platform to generate custom genome sequences through the use of AI and machine learning. The company’s platform, The Generate Platform, uses a library of proteins to generate genomes, based on generalized trends of naturally occurring sequencing. The platform can be used to generate novel medicines with specific therapeutic functions, across specialities and use cases, as through the sequencing of proteins, the platform is therefore able to generate antibodies and peptides, enzymes, and stealth proteins. As of May 2024, the company had generated 42,000 proteins, built them, and tested them.Key customers and partnershipsGenerate Biomedicines secured a partnership with Amgen in January 2022 through which both parties signed a multi-modality research collaboration agreement. Through the partnership, Amgen would pay USD 50 million in an upfront payment (with a possible deal value of up to USD 1.9 billion plus future royalties) for Generate Biomedicines to discover and develop protein therapeutics for five clinical targets across several therapeutic areas and modalities.Prior to the above, Generate’s latest partnership was with the University of Texas MD Anderson Cancer Center, which was signed in April 2023. The partnership was secured to accelerate the creation of novel protein therapeutics in oncology through the use of generative AI. Through the partnership, both parties would collaborate to co-discover protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.&nbsp;

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Generate Biomedicines leverages its AI/ML-powered drug generation platform to develop custom protein-based therapeutics. It creates novel proteins from scratch across a wide range of protein modalities, such as peptides, enzymes, antibodies, and gene therapies.&nbsp;
 
 
 The company reports that its platform resolves the historical issue of the immune system's unresponsiveness to new proteins. It learns how proteins are viewed by the immune system and can recode protein sequences to evade the immune system (ones which the immune system would otherwise eliminate because they are non-human proteins entering the body).
 
 
 The company mainly offers its AI platform to other drug developers to simplify and expedite the development process of protein therapeutics. It also has several drug candidates in its in-house pipeline targeting immunology, oncology, and infectious diseases. Two of the company&rsquo;s drug candidates, GB-0669 for SARS-CoV-2 and GB-0895 for asthma, have entered Phase I clinical trials.&nbsp;
 
 
 Key customers and partnerships
 
 
 Generate entered a USD 1.9 billion-worth multi-target collaboration with 
 <a href="https://sp-edge.com/updates/7637">
 Amgen
 </a>
 in January 2022 to jointly develop five novel drug targets across various therapeutic areas and modalities.&nbsp;
 
 
 It also partnered with the 
 <a href="https://generatebiomedicines.com/news/generatebiomedicines-and-md-anderson-enter-co-development-and-commercialization-agreement-to-accelerate-novel-protein-therapeutics-for-oncology-using-generative-ai">
 University of Texas MD Anderson Cancer Center
 </a>
 (April 2023) and 
 <a href="https://www.ns-healthcare.com/news/generatebiomedicines-roswell-park-partner-to-oncology-cell-therapies/">
 Roswell Park Comprehensive Cancer Center
 </a>
 (November 2023) to accelerate the creation of novel therapeutics (protein and chimeric antigen receptor [CAR] T-cell therapies) in oncology.&nbsp;
 
 
 Funding and financials
 
 
 In September 2023, the company raised USD 273 million in a 
 <a href="https://sp-edge.com/updates/21894">
 Series C
 </a>
 funding round led by Amgen to support the advancing of the company&rsquo;s pipeline of protein therapies and enhance its generative biology platform. 
 
</div>

Quantum information processing is slowly becoming a reality, ushering in a new technological era.

Quantum Computing

Quantinuum is a full-stack quantum computing company formed in November 2021, via a <a href="https://sp-edge.com/updates/7045">merger,</a> to leverage the hardware capabilities of Honeywell Quantum Solutions (HQS)—the quantum unit of Honeywell International—and the software expertise of Cambridge Quantum Computing (CQC).It offers quantum solutions in areas including cyber security and encryption, drug discovery and delivery, finance, and material science. All of Quantinuum’s products will be compatible with many quantum technologies including trapped ions (H1 computers) and superconducting qubits (IBM). Quantinuum also offers CQC’s open-source hardware-agnostic software development kit (SDK) TKET.&nbsp;Quantinuum’s H1 generation of trapped-ion quantum computers—H1-1 and H1-2—that are powered by Honeywell, are commercially available on the cloud. The 12-qubit H1-2 system is reportedly the first quantum computer to reach a <a href="https://sp-edge.com/updates/7513">quantum volume (QV) benchmark of 2,048.</a> In <a href="https://sp-edge.com/updates/28554">April 2024</a>, the company announced that its 20-qubit quantum processor H1-1 achieved the “three 9's,” a 99.9% two-qubit gate fidelity in a commercial quantum computer, making it the first in the industry to do so. It also surpassed a QV of 1 million, marking the highest at the time. Following this, in <a href="https://sp-edge.com/updates/30165">June 2024</a>, introduced H2-1, the industry's first quantum computer featuring 56 trapped-ion qubits, which efficiently performed Random Circuit Sampling (RCS) algorithms, exceeding the industry standard set by Google in 2019.The company, in December 2021, introduced “Quantum Origin,” a quantum-enhanced cryptographic key generation platform. It is reportedly the world’s first commercial product to be built by a quantum computer. It also commercially launched a computational chemistry software platform <a href="https://sp-edge.com/updates/10678">InQuanto</a> in May 2022.&nbsp;In <a href="https://sp-edge.com/updates/32103">July 2024</a>, the company was reportedly preparing for an IPO with a target valuation of USD 10 billion according to a Bloomberg report. This followed a USD 300 million equity<a href="https://sp-edge.com/updates/25586"> funding</a> round in January 2024 with a pre-money valuation of USD 5 billion.Key customers and partnershipsQuantinuum’s partnerships included <a href="https://sp-edge.com/updates/28181">Microsoft </a>(April 2024) to manufacture four logical qubits with low error rates; <a href="https://sp-edge.com/updates/24885">EAGLYS and Mitsui</a> (December 2023) to develop a platform that shields data and AI models from quantum-based cyber threats; <a href="https://sp-edge.com/updates/25860">Thales</a> (January 2024) to launch a PQC Starter Kit that helps business enterprises prepare for Post-Quantum Cryptography (PQC); <a href="https://sp-edge.com/updates/25400">RIKEN</a> (January 2024) to develop a hybrid quantum high-performance computing (quantum HPC) platform; <a href="https://sp-edge.com/updates/18994">HSBC</a> (May 2023) to explore quantum computing in real-world financial applications; and Mitsui (October 2022) to build the quantum computing market in Japan and the Asia-Pacific regions.Quantinuum also joined the <a href="https://sp-edge.com/updates/7594">Strangeworks ecosystem</a> in January 2022 to provide Quantum Origin access to Strangeworks and its customers.

Data Infrastructure & Analytics

<div>
 
 Data-mastering company Tamr is an enterprise data unification platform that is deemed cost-effective, scalable, and accessible to any enterprise. Deployed in production at a variety of organizations, including information services providers, pharmaceutical firms, and retailers, the company&rsquo;s cloud-native solutions offer an alternative to traditional Master Data Management (MDM) tools. Backed by investors like NEA and Google Ventures, Tamr lays the foundation for modern DataOps at many large organizations such as Toyota, Santander, and GSK.
 
</div>

Quantinuum is a quantum company dedicated to the advancement of quantum computers and the development of software solutions. Quantinuum's technology spearheads advancements in materials discovery, cybersecurity, and next-generation quantum AI. The company has nearly 500 professionals, including over 370 scientists and engineers, Quantinuum takes the helm in driving the quantum computing revolution globally.

Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Accure Health (''Accure'') is a privately held, next-generation precision medicine company. Accure is focused on developing AI-powered solutions that leverage patients' biomarker profiles to enable precision therapies delivered to the right cells for the right patients. Accure’s motto is ''Cure through Accuracy''.

Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for the expanded use of curative therapy with stem cell transplants and gene therapies. The company s novel engineered hematopoietic stem cells (eHSCs) platform aims to overcome the limitations of transplant grafts while also unlocking the potential of stem cells, potentially increasing the number of patients who could benefit from allogeneic and autologous gene-edited hematopoietic stem cell therapy. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.  SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

Keck Graduate Institute (KGI) is part of the prestigious Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field.

Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world.  BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more available for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy.  The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.

Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science, and environmental research. Nanopore sequencing is also being explored beyond research, where it has the potential to provide rapid, meaningful information in the fields of healthcare, agriculture, food and water surveillance, and education. Oxford Nanopore’s proprietary technology is fully scalable for any requirement.  Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long-read sequence data.   The benchtop GridION X5 can run up to five MinION Flow Cells at a time, on-demand, for larger genomics projects.  The recently launched PromethION is the largest format for nanopore sequencing, designed to offer on-demand use of up to 48 Flow Cells – each of which can offer more than 100Gb of sequencing data. Focusing on ease of use, nanopore sequencing offers easy and rapid preparation, including a ten-minute library preparation kit and the automated, programmable VolTRAX. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.

Tamr is an enterprise data unification company that is accessible to any enterprise. Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale and cost-effectively. Tamr is deployed in production at a variety of organizations, including information services providers, pharmaceutical firms, and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker, and Ihab Ilyas with George Beskales, Daniel Bruckner, and Alex Pagan.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000.

SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily rich talent pool. The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.

Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases. The company is values-based and deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious diseases. They offer products for treating illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

<div> Amgen Inc. (Nasdaq: AMGN) is one of the world's leading independent biotechnology companies, focused on developing innovative human therapeutics to treat serious illnesses. Founded in 1980, Amgen harnesses advances in human genetics and molecular biology to create medicines that address unmet medical needs in areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Amgen's key products include Prolia and Xgeva (denosumab) for bone disorders, Repatha (evolocumab) for cholesterol management, Otezla (apremilast) for inflammatory diseases, Enbrel (etanercept) for autoimmune diseases, and LUMAKRAS/LUMYKRAS (sotorasib) for lung cancer. The company has a robust pipeline of potential new medicines in development across its therapeutic focus areas. Amgen's product portfolio includes: <ul> <li> General Medicine: Repatha, Prolia, EVENITY, Aimovig </li> <li> Inflammation: TEZSPIRE, Otezla, Enbrel, AMJEVITA/AMGEVITA </li> <li> Oncology: BLINCYTO, Vectibix, KYPROLIS, LUMAKRAS/LUMYKRAS, XGEVA, Nplate </li> <li> Biosimilars: MVASI, KANJINTI </li> <li> Rare Disease: TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS </li> </ul> In 2023, Amgen acquired Horizon Therapeutics for USD 27.8 billion, adding rare disease treatments to its portfolio. The company continues to invest in research and development, with over USD 4 billion spent annually on R&amp;D in recent years. Amgen has a global presence with products sold in approximately 100 countries and regions worldwide. The company is headquartered in Thousand Oaks, California and is a component of both the Dow Jones Industrial Average and Nasdaq-100 index. </div>

Legal win leads Amgen to at-risk launch of Eylea biosimilar

Amgen Ventures

Reinventing gene therapies with next-generation technologies

Human Gene Editing

Companies that develop novel therapeutics based on the CRISPR/Cas9 gene-editing technology

Companies that develop novel therapeutics based on other types of gene editing technologies including TALEN and ZFN

Companies that develop systems that enable the diagnosis of gene-edited therapies. Also includes systems that deliver gene-editing components into the human body

Companies that offer their gene-editing platforms to other pharma companies to develop therapeutics

Companies that offer support services to gene-editing companies, which include genomic research companies, gene-editing component manufacturing, and designing tools

Bringing Life-Saving Biologics to More Patients

Biosimilars

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <ul>
 <li>California-based AI drug discovery company PostEra and Amgen have partnered for a multi-target drug discovery project.</li>
 <li>They will combine PostEra's AI platform Proton and Amgen's drug discovery skillset to advance up to five small molecule programs.</li>
 <li>Amgen will also have the option to use some of PostEra's AI technologies for its internal programs.</li>
 <li>The collaboration includes upfront and milestone payments and royalties on developed products.</li>
 <li>The specific terms of the agreement are undisclosed.</li>
 </ul>
 
</div>

Amgen

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless